Meeting
2023 ASCO Genitourinary Cancers Symposium
Phase 2, multicenter, randomized study of salvage radiation therapy +/- metformin for recurrent prostate cancer after radical prostatectomy (SAKK 08/15 – GETUG-AFU 34 PROMET trial).
Authors
Alan Dal Pra
University of Miami, Miami, FL
Alan Dal Pra , Stephane Supiot , Katrin Gysel , Thomas Zilli , Richard Cathomas , Thomas Reynaud , Pascal Pommier , Paul Martin Putora , Davide Giovanni Bosetti , Matthias Guckenberger , Guido Hildebrandt , Sabrina Chiquet , Meryem Brihoum , Alexandros Papachristofilou , Stefanie Hayoz , Pirus Ghadjar , Daniel Rudolf Zwahlen , Silke Gillessen , Aurelius Gabriel Omlin , Daniel M. Aebersold
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02945813
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 353)
DOI
10.1200/JCO.2023.41.6_suppl.353
Abstract #
353
Poster Bd #
M11
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.
First Author: Alan Dal Pra
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2021 Genitourinary Cancers Symposium
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2019 ASCO Annual Meeting
A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).
First Author: Tian Zhang